Flerie Invest AB has increased its holding in Xintela AB, whereby the lim-it for mandatory bidding has been exceeded

THIS PRESS RELEASE DOES NOT CONSTITUTE A PUBLIC TENDER OFFER OR OTHERWISE AN OFFER TO ACQUIRE SHARES

Flerie Invest AB ("Flerie Invest") has acquired an additional 33,200,000 shares in Xintela AB ("Xintela") at a subscription price of SEK 0.25 per share through a directed share issue in Xintela, which was resolved by the board of directors of Xintela on 18 July 2022 and approved by the extraordinary general meeting on 3 August 2022.

Flerie Invest has previously acquired 71,406,962 shares in Xintela at a subscription price of SEK 0.25 after subscription without preferential rights in the rights issue resolved by the board of directors of Xintela on 20 May 2022.

Flerie Invests total holding in Xintela following the acquisition amounts to 34 per cent of the shares and votes of the company. The limit for mandatory bidding has thus been exceeded. Flerie Invest intends to revert with information about a possible public takeover bid regarding the remaining shares in Xintela within four weeks.

"We are pleased to increase our long-term commitment to Xintela and look forward to contributing to the success of the important medicines the company is developing" says Thomas Eldered, Flerie Invest.

For further information, please contact:

Thomas Eldered, President or Cecilia Scheele, CFO

Both can be contacted at [email protected]  +46 (0)76 131 0127

This information was submitted for publication on 4 August 2022 at 08:00 CEST.

About Flerie Invest AB

Flerie Invest is an active long-term global biotech and pharma investor based in Stockholm and London managing a portfolio of around 30 companies in Europe, Israel and the US. The focus is on enabling pioneering organisations operating in the drug development and services space to succeed by providing them with resources and expertise.

The portfolio includes a wide range of areas, including immuno-oncology, metabolic diseases and biologics development and manufacturing organisations, which have the potential to make a significant impact on health and wellbeing. Flerie Invest was founded in 2010 by Thomas Eldered, who also co-founded and built Recipharm to be one of the world's top five pharmaceutical contract manufacturers. For more information, please visit www.flerie.com.

Flerie Invest AB har ökat sitt innehav i Xintela AB varigenom gränsen för budplikt passerats

DETTA PRESSMEDDELANDE UTGÖR INTE ETT OFFENTLIGT UPPKÖPSERBJUDANDE ELLER ANNARS ETT ERBJUDANDE OM ATT FÖRVÄRVA AKTIER

Flerie Invest AB ("Flerie Invest") har förvärvat ytterligare 33 200 000 aktier i Xintela AB ("Xintela") till en teckningskurs om 0,25 kronor per aktie i en riktad nyemission i Xintela, vilken beslutades av styrelsen i Xintela den 18 juli 2022 och godkändes av den extra bolagsstämman den 3 augusti 2022.


Flerie Invest AB has increased its holding in Xintela AB, whereby the lim-it for mandatory bidding has been exceeded

THIS PRESS RELEASE DOES NOT CONSTITUTE A PUBLIC TENDER OFFER OR OTHERWISE AN OFFER TO ACQUIRE SHARES

Flerie Invest AB ("Flerie Invest") has acquired an additional 33,200,000 shares in Xintela AB ("Xintela") at a subscription price of SEK 0.25 per share through a directed share issue in Xintela, which was resolved by the board of directors of Xintela on 18 July 2022 and approved by the extraordinary general meeting on 3 August 2022.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted